David Leslie Szekeres - Jan 13, 2023 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)

Signature
/s/ Lisa Peraza Attorney-in-fact for David Szekeres
Stock symbol
HRTX
Transactions as of
Jan 13, 2023
Transactions value $
-$965
Form type
4
Date filed
1/17/2023, 04:37 PM
Previous filing
Oct 17, 2022
Next filing
Jan 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRTX Common Stock Other $5.41K +1.65K +7.99% $3.27 22.3K Oct 31, 2022 Direct F1
transaction HRTX Common Stock Options Exercise +1.25K +5.59% 23.6K Jan 13, 2023 Direct F2
transaction HRTX Common Stock Options Exercise +4.56K +19.34% 28.2K Jan 13, 2023 Direct F2
transaction HRTX Common Stock Tax liability -$6.38K -2.01K -7.14% $3.17 26.2K Jan 13, 2023 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRTX Restricted Stock Units Options Exercise $0 -1.25K -12.5% $0.00 8.75K Jan 13, 2023 Common Stock 1.25K Direct F2, F4
transaction HRTX Restricted Stock Units Options Exercise $0 -4.56K -12.31% $0.00 32.5K Jan 13, 2023 Common Stock 4.56K Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2022.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
F4 The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
F5 The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).